We are disrupting traditional advanced materials research and development for fields such as aerospace, defense, healthcare, mobility, recreation, and renewable energy.
Don’t see your position here? We’d still like to hear from you.
careers@cambiomat.com
Chief Technology Officer
Andrew spent 17 years as a materials engineer and chemical engineer in US Department of the Navy and US Department of the Air Force research laboratories. He also has several years of commercial experience developing industrial materials for companies large and small. Andrew is a co-creator of Cambium’s first bio-discovered materials technologies.
He has won several awards for science and technology management in recognition of his efforts in developing “game-changing” fuel processing technology for overseas combatant commands. In 2016 he was named the US Department of Defense Laboratory Scientist of the Quarter for his contributions to the development of high-performance materials for aerospace and defense applications.
Andrew is a humble Midwesterner who earned his PhD in polymer engineering from The University of Akron and BS in chemical engineering from Case Western Reserve University.
Co-founder
Stephan has held senior and executive leadership & strategy roles in a wide range of biotech firms, most of them publicly held, each of them pioneers in their own right in novel platforms such as synthetic biology, nanotechnology, RNAi, and fermentation-produced specialty ingredients.
He has been part of billion-dollar merger transactions with big pharma; participated as a delegate at the United Nations Convention on Biological Diversity; and is a sustainability/product-life-cycle expert. Before that he was an investigative reporter for nearly 20 years covering all aspects of biotechnology.
Stephan is a mountain man from Colorado who earned his MS at the Columbia University Graduate School of Journalism, and his BS in Business & Economics at Colorado State University.
Co-founder & CEO
Simon is the co-founder and CEO of Cambium Biomaterials. Previously Simon ran two synthetic biology companies that developed biological production routes to high-value molecules. He was the co-Founder and CEO of Abunda, which was sold to Evolva, a Swiss publicly-traded company. He subsequently became Evolva’s COO and then its CEO.
Prior to this, Simon spent more than a decade in venture capital investing across materials, life sciences and related technologies in the US, Europe and Israel. Before that he was Product Development Manager for Zeneca’s biopolymers business and Senior Research Scientist for ICI Advanced Materials specializing in surface and adhesion science.
Simon is a Yorkshireman with a PhD in physics from the University of Liverpool, UK and an MBA from Harvard Business School.
